We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.57%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.92B
AUM Growth
+$129M
Cap. Flow
+$265M
Cap. Flow %
13.75%
Top 10 Hldgs %
49.82%
Holding
94
New
22
Increased
32
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$65.4M
2
EW icon
Edwards Lifesciences
EW
+$64.1M
3
RAPP
Rapport Therapeutics
RAPP
+$45.2M
4
ALGN icon
Align Technology
ALGN
+$34.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$23M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$85.9M
2
INCY icon
Incyte
INCY
+$75.6M
3
ARGX icon
argenx
ARGX
+$58.8M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$45.5M
5
PODD icon
Insulet
PODD
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
26
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$23.2M 1.2%
250,000
-600,000
-71% -$53.8M
SLNO
27
DELISTED
Soleno Therapeutics
SLNO
$22.6M 1.18%
554,359
+403,584
+268% +$17.1M
ISRG icon
28
PUT
Intuitive Surgical
ISRG
$121B
$22.2M 1.16%
+50,000
New +$19.9M
SVRA icon
29
Savara
SVRA
$1.13B
$21.6M 1.12%
5,358,918
+3,011,657
+128% +$13.4M
CLDX icon
30
Celldex Therapeutics
CLDX
$2.77B
$20.3M 1.05%
547,707
-254,070
-32% -$9.59M
ROIV icon
31
Roivant Sciences
ROIV
$25.2B
$19.7M 1.03%
1,868,412
+866,708
+87% +$9.5M
ESTA icon
32
Establishment Labs
ESTA
$2.72B
$19.5M 1.01%
429,244
+288,082
+204% +$14.6M
INZY
33
DELISTED
Inozyme Pharma
INZY
$19.1M 0.99%
4,280,308
– –
RVMD icon
34
Revolution Medicines
RVMD
$40.2B
$17.7M 0.92%
+455,099
New +$17M
KURA icon
35
Kura Oncology
KURA
$922M
$17M 0.88%
825,243
+323,303
+64% +$6.65M
INSM icon
36
Insmed
INSM
$23.2B
$15.3M 0.79%
+227,747
New +$8.83M
BSX icon
37
Boston Scientific
BSX
$65.8B
$13.2M 0.68%
171,080
-182,771
-52% -$13.4M
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.6B
$12.4M 0.65%
44,417
+25,388
+133% +$6.04M
PODD icon
39
Insulet
PODD
$11.3B
$12.3M 0.64%
60,967
-159,236
-72% -$28.7M
ALNY icon
40
CALL
Alnylam Pharmaceuticals
ALNY
$36.3B
$12.2M 0.63%
+50,000
New +$7.89M
PHVS icon
41
Pharvaris
PHVS
$2.39B
$11.3M 0.59%
601,534
+16,862
+3% +$343K
AXNX
42
DELISTED
Axonics, Inc. Common Stock
AXNX
$10.1M 0.53%
150,490
+1,105
+0.7% +$74.4K
IMTX icon
43
Immatics
IMTX
$1.24B
$9.26M 0.48%
796,704
-1,366,942
-63% -$15.4M
CABA icon
44
Cabaletta Bio
CABA
$439M
$9.13M 0.47%
1,220,400
+790,654
+184% +$9.69M
PEPG icon
45
PepGen
PEPG
$133M
$8.96M 0.47%
561,128
+57,504
+11% +$824K
EWTX icon
46
Edgewise Therapeutics
EWTX
$4.39B
$8.57M 0.45%
+475,691
New +$8.3M
IMNM icon
47
Immunome
IMNM
$2.52B
$7.93M 0.41%
655,680
+61,284
+10% +$959K
EXAS
48
DELISTED
Exact Sciences
EXAS
$7.68M 0.4%
181,828
-47,653
-21% -$2.62M
NARI
49
DELISTED
Inari Medical, Inc. Common Stock
NARI
$7.5M 0.39%
155,838
+145,622
+1,425% +$6.45M
DXCM icon
50
DexCom
DXCM
$27.6B
$6.97M 0.36%
+61,494
New +$7.77M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2024 Portfolio in Review

As of Q2 2024, Sofinnova Investments held 94 positions worth $1.92B, up 7.2% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments deployed $265M of net new capital in Q2 2024, opening 22 new positions and adding to 32 existing holdings. Its largest new stake was Stryker: 193,084 shares worth $65.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Insulet, an estimated $28.7M trimmed.

  • Sofinnova Investments's largest Q2 2024 buy was Stryker: 193,084 shares worth $65.7M.
  • Sofinnova Investments added most to Align Technology in Q2 2024, an estimated $34.3M increase.
  • Sofinnova Investments's biggest Q2 2024 reduction was Insulet, cutting an estimated $28.7M.
  • Sofinnova Investments fully exited Merck in Q2 2024, selling an estimated $85.9M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.92B portfolio in Q2 2024.
  • Sofinnova Investments opened 22 new positions and closed 13 in Q2 2024.
  • Sofinnova Investments's portfolio value rose 7.2% quarter-over-quarter to $1.92B.

Based on Sofinnova Investments's 13F filing for Q2 2024, filed 9 Aug 2024.